Anna Kazanchyan, MD
Founder and Chief Executive Officer, Saghmos Therapeutics
Anna Kazanchyan, MD, is CEO and Founder of Saghmos Therapeutics. The company has a Phase 3-ready cardiorenal metabolic modulator for reducing the risk of Acute Kidney Injury and Major Adverse Cardiac and Kidney Events after contrast procedures such as percutaneous coronary intervention. Previously, she was SVP, Business Development and SVP, Product Development at Ovid Therapeutics (OVID). She was Founder and Managing Partner of Primary i-Research, where she was an executive advisor to biopharmaceutical companies. Previously, Dr. Kazanchyan was Senior Biotechnology Analyst at Wells Fargo and was a member of the Institutional-Investor ranked Biotechnology Equity Research teams at Goldman Sachs and Citi. She received an MD from Harvard Medical School.